PE20180771A1 - Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina - Google Patents

Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina

Info

Publication number
PE20180771A1
PE20180771A1 PE2018000003A PE2018000003A PE20180771A1 PE 20180771 A1 PE20180771 A1 PE 20180771A1 PE 2018000003 A PE2018000003 A PE 2018000003A PE 2018000003 A PE2018000003 A PE 2018000003A PE 20180771 A1 PE20180771 A1 PE 20180771A1
Authority
PE
Peru
Prior art keywords
particles
virus
gag protein
bovine immunodeficiency
immunodeficiency virus
Prior art date
Application number
PE2018000003A
Other languages
English (en)
Spanish (es)
Inventor
Peter Pushko
Irina Tretyakova
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Publication of PE20180771A1 publication Critical patent/PE20180771A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/866Baculoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/14011Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
PE2018000003A 2015-07-02 2016-07-01 Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina PE20180771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
PE20180771A1 true PE20180771A1 (es) 2018-05-07

Family

ID=57609369

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000003A PE20180771A1 (es) 2015-07-02 2016-07-01 Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina

Country Status (13)

Country Link
US (2) US11576965B2 (enExample)
EP (1) EP3316906A4 (enExample)
JP (2) JP6978079B2 (enExample)
KR (1) KR20180032586A (enExample)
CN (2) CN108348596B (enExample)
BR (1) BR112018000037A2 (enExample)
CA (1) CA2991213A1 (enExample)
EA (1) EA201890187A1 (enExample)
MA (1) MA42312A (enExample)
MX (1) MX390927B (enExample)
PE (1) PE20180771A1 (enExample)
RU (2) RU2757723C2 (enExample)
WO (1) WO2017004586A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
EP1576143B1 (en) 2002-05-17 2010-11-24 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20100247574A1 (en) 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
SG10201903161XA (en) 2007-05-29 2019-05-30 Christopher Reid Methods for production and uses of multipotent cell populations
AU2008275895A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella Zoster Virus-virus like particles (VLPS) and antigens
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US20110293700A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Also Published As

Publication number Publication date
CN108348596A (zh) 2018-07-31
RU2757723C2 (ru) 2021-10-21
JP2020198893A (ja) 2020-12-17
US20230310579A1 (en) 2023-10-05
US12303560B2 (en) 2025-05-20
MA42312A (fr) 2018-05-09
WO2017004586A1 (en) 2017-01-05
MX2018000023A (es) 2018-08-15
RU2020125098A3 (enExample) 2020-12-11
BR112018000037A2 (pt) 2018-09-04
CN108348596B (zh) 2022-08-23
CA2991213A1 (en) 2017-01-05
CN115927212A (zh) 2023-04-07
RU2018103757A (ru) 2019-08-05
JP2018525028A (ja) 2018-09-06
EA201890187A1 (ru) 2018-06-29
RU2020125098A (ru) 2020-09-04
RU2734118C2 (ru) 2020-10-13
US20180369364A1 (en) 2018-12-27
KR20180032586A (ko) 2018-03-30
EP3316906A1 (en) 2018-05-09
RU2018103757A3 (enExample) 2019-12-09
EP3316906A4 (en) 2019-01-02
HK1259067A1 (zh) 2019-11-22
JP6978079B2 (ja) 2021-12-08
US11576965B2 (en) 2023-02-14
MX390927B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
MX2025009360A (es) Medios y metodo para preparar vectores virales y usos de los mismos
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
PE20171133A1 (es) Particulas tipo virus modificadas de cmv
EA201790630A1 (ru) Способы получения рибозидов
IL282411A (en) Methods for analysis of viral capsid protein composition
EA201990071A1 (ru) Композиция пептидной вакцины
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
UY40283A (es) Método para alterar una propiedad de una planta
CY1124143T1 (el) Οστικες μορφογενετικες πρωτεϊνες
MY191322A (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EP3770604A3 (en) Flow cytometry method for evaluating biological material for unassociated virus-size particles of influenza virus viral type
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
MX383330B (es) Particula tipo virus de flavivirus.
PE20180771A1 (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
NZ752893A (en) Synthetic chimeric poxviruses
PL3504225T3 (pl) Nowe antygeny białkowe otoczki ludzkiego wirusa niedoboru odporności eksprymowane przez ssaki
MX2021003392A (es) Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados.
MX2018003445A (es) Expresion de proteinas que contienen fc.
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación

Legal Events

Date Code Title Description
FD Application declared void or lapsed